Abonnement à la biblothèque: Guest
Critical Reviews™ in Eukaryotic Gene Expression

Publication de 6  numéros par an

ISSN Imprimer: 1045-4403

ISSN En ligne: 2162-6502

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.6 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.2 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00058 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.33 SJR: 0.345 SNIP: 0.46 CiteScore™:: 2.5 H-Index: 67

Indexed in

Nucleic Acid Modulation of Gene Expression: Approaches for Nucleic Acid Therapeutics Against Cancer

Volume 15, Numéro 2, 2005, pp. 163-182
DOI: 10.1615/CritRevEukaryotGeneExpr.v15.i2.50
Get accessGet access

RÉSUMÉ

Most cancers are characterized by abnormal gene expression, which is thought to contribute to the pathogenesis and maintenance of the malignant phenotype; abnormal proliferation, maturation, and apoptosis. Silencing such genes would appear to be a rational approach to the therapy of cancer, and some preliminary clinical studies support this concept. Of the strategies available, the anti-mRNA gene silencing approach has attracted much attention and is the focus of this review. This strategy includes three types of agents: (1) single-stranded antisense oligonucleotides; (2) catalytically active oligonucleotides, such as ribozymes, and DNAzymes that possess inherent RNA cleaving activity; and (3) small interfering RNA (siRNA) molecules that induce RNA interference (RNAi). Among these agents, antisense oligonucleotides, especially phosphorothioate (PS) oligonucleotides, have been the most frequently used in clinical trials. In this article, we provide an overview of anti-mRNA gene silencing agents and their development for use as cancer therapeutics.

CITÉ PAR
  1. Chonco Louis, Bermejo-Martín Jesus F., Ortega Paula, Shcharbin Dzmitry, Pedziwiatr Elzbieta, Klajnert Barbara, Javier de la Mata F., Eritja Ramon, Gómez Rafael, Bryszewska Maria, Angeles Muñoz-Fernandez Ma, Water-soluble carbosilane dendrimers protect phosphorothioate oligonucleotides from binding to serum proteins, Org. Biomol. Chem., 5, 12, 2007. Crossref

  2. Papsai Pal, Aldag Jasmin, Persson Tina, Elmroth Sofi K. C., Kinetic preference for interaction of cisplatin with the G–C-rich wobble basepair region in both tRNAAlaand MhAla, Dalton Trans., 29, 2006. Crossref

  3. Schiffelers Raymond M, Storm Gert, ICS-283: a system for targeted intravenous delivery of siRNA, Expert Opinion on Drug Delivery, 3, 3, 2006. Crossref

  4. Li Jing, Zhu Zhenping, Research and development of next generation of antibody-based therapeutics, Acta Pharmacologica Sinica, 31, 9, 2010. Crossref

  5. Toub Nedjma, Bertrand Jean-Rémi, Malvy Claude, Fattal Elias, Couvreur Patrick, Antisense Oligonucleotide Nanocapsules Efficiently Inhibit EWS-Fli1 Expression in a Ewing's Sarcoma Model, Oligonucleotides, 16, 2, 2006. Crossref

  6. Fuessel Susanne, Meye Axel, Kraemer Kai, Kunze Doreen, Hakenberg Oliver W., Wirth Manfred P., Synthetic Nucleic Acids as Potential Therapeutic Tools for Treatment of Bladder Carcinoma, European Urology, 51, 2, 2007. Crossref

  7. Pershouse Mark A., Heivly Shane, Girtsman Teri, The Role of SV40 in Malignant Mesothelioma and Other Human Malignancies, Inhalation Toxicology, 18, 12, 2006. Crossref

  8. Niewiarowska J, Sacewicz I, Wiktorska M, Wysocki T, Stasikowska O, Wagrowska-Danilewicz M, Cierniewski C S, DNAzymes to mouse β1 integrin mRNA in vivo: targeting the tumor vasculature and retarding cancer growth, Cancer Gene Therapy, 16, 9, 2009. Crossref

Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections Prix et politiques d'abonnement Begell House Contactez-nous Language English 中文 Русский Português German French Spain